Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Friday, Marketbeat Ratings reports. They currently have a $18.00 price target on the stock, up from their prior price target of $15.00. HC Wainwright’s target price indicates a potential upside of 65.14% from the stock’s previous close. The analysts noted that the move was a valuation call.

A number of other research firms have also weighed in on AXSM. Zacks Investment Research lowered Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, January 14th. BTIG Research lifted their target price on Axsome Therapeutics to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 8th. ValuEngine raised Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. Cantor Fitzgerald set a $16.00 price objective on Axsome Therapeutics and gave the stock a “buy” rating in a report on Monday, December 10th. Finally, BidaskClub lowered Axsome Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, March 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $24.75.

Shares of Axsome Therapeutics stock opened at $10.90 on Friday. Axsome Therapeutics has a 52-week low of $1.94 and a 52-week high of $11.00. The stock has a market capitalization of $324.96 million, a P/E ratio of -8.79 and a beta of 3.32. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 6.00.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.01. As a group, sell-side analysts forecast that Axsome Therapeutics will post -1.13 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Barclays PLC bought a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $30,000. Bank of New York Mellon Corp bought a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $98,000. Worth Venture Partners LLC bought a new stake in Axsome Therapeutics in the third quarter valued at approximately $138,000. BlackRock Inc. lifted its position in Axsome Therapeutics by 14.6% in the fourth quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock valued at $181,000 after purchasing an additional 8,137 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $871,000. Institutional investors own 12.84% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Recommended Story: Cryptocurrencies

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.